SML0233
Ro 61-8048
≥98% (HPLC)
別名:
3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-benzenesulfonamide, 3,4-Dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide, Ro-61-8048
ログイン組織・契約価格を表示する
すべての画像(1)
About This Item
実験式（ヒル表記法）:
C17H15N3O6S2
CAS番号:
分子量:
421.45
MDL番号:
UNSPSCコード:
12352200
PubChem Substance ID:
NACRES:
NA.77
おすすめの製品
品質水準
アッセイ
≥98% (HPLC)
フォーム
powder
色
faintly yellow to yellow
溶解性
DMSO: ≥15 mg/mL
保管温度
2-8°C
SMILES記法
COc1ccc(cc1OC)S(=O)(=O)Nc2nc(cs2)-c3cccc(c3)[N+]([O-])=O
InChI
1S/C17H15N3O6S2/c1-25-15-7-6-13(9-16(15)26-2)28(23,24)19-17-18-14(10-27-17)11-4-3-5-12(8-11)20(21)22/h3-10H,1-2H3,(H,18,19)
InChI Key
NDPBMCKQJOZAQX-UHFFFAOYSA-N
関連するカテゴリー
アプリケーション
Ro 61-8048 has been used as a kynurenine 3-monooxygenase (KMO) inhibitor to study its effects on nicotinamide adenine dinucleotide (NAD+) concentration in hepatocytes of mice.
生物化学的／生理学的作用
Inhibition of kynurenine 3-hydroxylase by Ro 61-8048 reduces the episodes of dystonia and dyskinesias induced by decreased levels of kynurenic acid.
Ro 61-8048 is a potent kynurenine 3-monooxygenase (KMO) inhibitor
Ro 61-8048 is an inhibitor of kynurenine 3-monooxygenase (KMO) that increases kynurenic acid levels and reduces extracellular glutamate in the brain.
保管分類コード
11 - Combustible Solids
WGK
WGK 3
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
SML0233-5MG:
SML0233-25MG:
SML0233-VAR:
SML0233-IP:
SML0233-BULK:
最新バージョンのいずれかを選択してください：
Francesca M Notarangelo et al.
Developmental neuroscience, 41(1-2), 102-111 (2019-05-23)
Several lines of evidence support the hypothesis that abnormally elevated brain levels of kynurenic acid (KYNA), a metabolite of the kynurenine pathway (KP) of tryptophan degradation, play a pathophysiologically significant role in schizophrenia and other major neurodevelopmental disorders. Studies in
Paul B Larkin et al.
Biochimica et biophysica acta, 1860(11 Pt A), 2345-2354 (2016-07-10)
In mammals, the majority of the essential amino acid tryptophan is degraded via the kynurenine pathway (KP). Several KP metabolites play distinct physiological roles, often linked to immune system functions, and may also be causally involved in human diseases including
Melanie Hamann et al.
European journal of pharmacology, 586(1-3), 156-159 (2008-03-21)
Striatal dysfunctions seem to play a key role in the pathophysiology of dystonia in the dt(sz) mutant hamster, a model of paroxysmal non-kinesigenic dyskinesia, in which stress precipitates dystonic episodes. Previous examinations have shown changes in kynurenic acid levels and
Angelika Richter et al.
European journal of pharmacology, 478(1), 47-52 (2003-10-14)
The effects of the novel kynurenine 3-hydroxylase inhibitor 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro 61-8048) on severity of dystonia were examined in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress precipitates dystonic episodes. Ro 61-8048 (50, 100 and 150 mg/kg
Arghya Ray et al.
Leukemia, 34(2), 567-577 (2019-08-30)
Our prior studies showed that dysfunctional plasmacytoid dendritic cells (pDCs) contribute to multiple myeloma (MM) pathogenesis. Specifically, pDC interactions with tumor and T/NK effector cells in the bone marrow (BM) milieu induce immune suppression and MM cell proliferation. Delineation of
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）